American Journal of Physiology Renal Physiology

Lowering a protein reduced kidney injury in young but not aged mice

In a three-day experiment, reducing a protein on fat-storage droplets protected young mice’s kidneys from cisplatin, a chemotherapy drug, but did not protect 20-month-old mice.

Paper by Saiya Zhu, Chen Dai, Kelly Zheng, +5 more authorsDong Feng Zhou · University of Connecticut

Our read

Mechanisms
Studied:
Experiments in young and aged mice, three days, against control mice given cisplatin
What changed:
Reducing perilipin 2 lowered kidney injury in young mice compared with control mice, but did not protect aged mice
The catch:
Kidney injury was assessed only three days after cisplatin
In the record:
One of 30 papers on PLIN2 on record: 3 with results in people, 2 in animals.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

Young male and female C57BL/6 mice and 20-month-old mice underwent an experiment targeting perilipin 2, a protein on fat-storage droplets inside cells. Researchers gave a gene-silencing injection at 1 milligram per kilogram one day before a single cisplatin dose of 30 milligrams per kilogram. They assessed kidney injury three days after cisplatin.

Compared with control mice given cisplatin, young mice with reduced perilipin 2 had better blood-test results for kidney function, less tissue damage, fewer dying kidney cells and less inflammation. Reducing the protein did not protect aged mice, even though cisplatin increased its levels more strongly in aged kidneys. Protein measurements in young mice suggested enhanced ketogenesis, the production of ketones, an alternative fuel.

Why it matters

Cisplatin-related kidney injury can limit cancer treatment, particularly in older patients. The authors concluded that age-related differences in kidneys’ ability to adjust fuel use matter for vulnerability to injury and responses to potential therapies.

Caveats

This was a short-term mouse experiment, with gene silencing given before cisplatin rather than after injury developed. It did not test whether reducing perilipin 2 protects people receiving chemotherapy.

Comments

Be the first to comment.